EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combating yellow fever virus with 7-deaza-7-fluoro-2′-C-methyladenosine

Julia C LeCher iD, Vivian Vasconcelos Costa, Lauren N Rust, Leda C Bassit, Dharmeshkumar Patel iD, Sahar Rezaei, Justin Moua, Felipe Rocha da Silva Santos, Matheus Rodrigues Goncalves, Celso Martins Queroz-Junior, Fernanda Martins Marim, Longhu Zhou und 10 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01889-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Julia C LeCher und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's…. Hauptthemen laut MEDLINE: Yellow fever virus, Antiviral Agents, Yellow Fever, Adenosine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Science and Technology in Dengue and Host-Microorganism Interaction, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yellow fever virus (YFV) is a deadly zoonotic flavivirus endemic in tropical/sub-tropical Africa and South America transmitted by mosquito vector ( Aedes aegypti ; Haemagogus leucocelaenus ) to humans and non-human primates. There are no approved antiviral agents for YFV. We previously identified 7-deaza-7-fluoro-2′-C-methyladenosine (DFA) with anti-YFV activity. Interestingly, DFA exhibits pan-activity in vitro against flaviviruses, such as dengue, Japanese encephalitis, Zika, and hepatitis C. This study aimed to expand DFA’s anti-flavivirus profile. DFA exhibited potent sub-micromolar anti-YFV activity in vitro against both the vaccine strain (YFV-17D) and a viscerotropic clinical YFV isolate (DakH1279) concomitantly with low cellular cytotoxicity and no notable mitochondrial toxicity. In vivo , efficacy was assessed against both YFV-17DD and a human clinical isolate in A129 and AG129 mouse flavivirus infection models, respectively. DFA significantly reduced virus replication in the livers of YFV-infected mice and the hallmarks of YFV-induced liver damage, including alanine transaminase levels and indocyanine green clearance. Collectively, this work identifies DFA as a potent YFV inhibitor and lays the groundwork for further therapeutic development as a YFV and, potentially, pan-flavivirus therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yellow fever virusAntiviral AgentsYellow FeverAdenosineTubercidinAnimalsMiceHumansVero CellsVirus ReplicationChlorocebus aethiops

Stichwörter der Autor:innen

2-FBUDFAantiviral agentsflavivirusnucleoside analogsyellow fever virus

Substanzen

Antiviral AgentsAdenosineTubercidin

Autor:innen und Institutionen

  • Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Department of Morphology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, State of Minas Gerais, Brazil.
  • Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

ORCID-Profile: Julia C LeCher, Dharmeshkumar Patel, Mauro M Teixeira, Raymond F Schinazi

Förderung

  • NIH HHS
  • National Institute of Science and Technology in Dengue and Host-Microorganism Interaction
  • NIAID NIH HHS
  • Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
  • National Institutes of Health

Zitieren

APA

LeCher, J. C., Costa, V. V., Rust, L. N., Bassit, L. C., Patel, D., Rezaei, S., Moua, J., Santos, F. R. S., Goncalves, M. R., Queroz-Junior, C. M., Marim, F. M., Zhou, L., Lee, S., McBrayer, T., De, R., Azadi, N., Salman, M., Zandi, K., Amblard, F., …, & Schinazi, R. F. (2025). Combating yellow fever virus with 7-deaza-7-fluoro-2′-C-methyladenosine. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01889-24

Vancouver

LeCher JC, Costa VV, Rust LN, Bassit LC, Patel D, Rezaei S, et al. Combating yellow fever virus with 7-deaza-7-fluoro-2′-C-methyladenosine. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01889-24

BibTeX
@article{LeCher2025,
  author = {LeCher, Julia C and Costa, Vivian Vasconcelos and Rust, Lauren N and Bassit, Leda C and Patel, Dharmeshkumar and Rezaei, Sahar and Moua, Justin and Santos, Felipe Rocha da Silva and Goncalves, Matheus Rodrigues and Queroz-Junior, Celso Martins and Marim, Fernanda Martins and Zhou, Longhu and Lee, Sujin and McBrayer, Tamara and De, Ramyani and Azadi, Niloufar and Salman, Mohammad and Zandi, Keivan and Amblard, Franck and Burwitz, Benjamin and Teixeira, Mauro M and Schinazi, Raymond F},
  title = {Combating yellow fever virus with 7-deaza-7-fluoro-2′-C-methyladenosine},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01889-24}
}
Kostenlos starten →